This study indicates that with regard to EGFR and cytoplasmic galectin-3 immunoexpression, multiple marker testing may be an adjunct in the identification of high-risk ovarian serous cancers [20]. The gene discussed is EGFR; the disease is ovarian serous adenocarcinoma.